Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17559448 | 0.99 | MCHR1 (0.53) | MCHR1PDK2USP30NPY5RL3MBTL3 | |
| SCHEMBL95193 | 0.87 | MCHR1 (0.53) | MCHR1PDK2USP30NPY5RL3MBTL3 | |
| SCHEMBL6538705 | 0.87 | CCR5 (0.57) | MCHR1PDK2NPY5RL3MBTL3CCR5 | |
| Lithium Ion SCHEMBL17559446 | 0.86 | MCHR1 (0.52) | MCHR1PDK2USP30NPY5RL3MBTL3 | |
| SCHEMBL17559476 | 0.85 | PDK2 (0.52) | MCHR1PDK2USP30NPY5RL3MBTL3 | |
| SCHEMBL17572925 | 0.85 | USP30 (0.52) | MCHR1PDK2USP30L3MBTL3CCR5 | |
| SCHEMBL17559455 | 0.83 | USP30 (0.51) | MCHR1PDK2USP30L3MBTL3CCR5 | |
| SCHEMBL20955964 | 0.78 | PDK2 (0.66) | MCHR1PDK2USP30L3MBTL3 | |
| SCHEMBL18924383 | 0.77 | ALDH1A1 (0.53) | USP30 | |
| SCHEMBL562825 | 0.77 | POLB (0.50) | MCHR1PDK2NPY5RL3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | MCHR1 2275/4885PDK2 2493/4885USP30 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.